Sort   by:  
 Page size 
UnknownEfficacy of adavosertib therapy against anaplastic thyroid cancer.
Not available
S-EPMC8197631 | biostudies-literature
UnknownEfficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer.
Not available
S-EPMC8306685 | biostudies-literature
UnknownAdavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
Not available
S-EPMC10618648 | biostudies-literature
UnknownTranscriptionally distinct malignant neuroblastoma populations show selective response to adavosertib treatment.
Not available
S-EPMC12047484 | biostudies-literature
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Phosphoproteomics
PARP1 inhibitors (PARP1is ) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, ...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020484 | Pride
Adavosertib Phosphoproteomics Parp16 Lung cancer Parp1 Polypharmacology Parp inhibitor Ewing’s sarcoma Off-target Talazoparib 
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Expression Proteomics
PARP1 inhibitors (PARP1is ) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, ...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020485 | Pride
Adavosertib Parp16 Parp1 Small cell lung cancer Polypharmacology Parp inhibitor Proteomics Off-target Talazoparib 
UnknownPhase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.
Not available
S-EPMC12269869 | biostudies-literature
UnknownPhase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
Not available
S-EPMC10807611 | biostudies-literature
UnknownEffect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
Not available
S-EPMC7338825 | biostudies-literature
UnknownPhase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma.
Not available
S-EPMC11913579 | biostudies-literature
Sort   by:  
 Page size